Chen Xiaoying, Liu Xin, Ren Wenyan, Li Hongyan, Yang Siyun
Department of Pharmacy, Nanchong Key Laboratory of Individualized Drug Therapy, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital, Nanchong, China.
Department of Laboratory, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital, Nanchong, China.
Front Microbiol. 2025 May 15;16:1587132. doi: 10.3389/fmicb.2025.1587132. eCollection 2025.
This study aims to investigate the distribution and drug resistance of Gram-negative bacteria in the intensive care unit (ICU) of a tertiary general hospital in Sichuan Province, with the goal of promoting rational antibiotic use and reducing multidrug resistance.
A retrospective analysis was conducted on the distribution and drug resistance of Gram-negative bacteria in ICU samples collected from January 2019 to December 2024.
A total of 83,944 culture samples were analyzed, primarily blood (45.27%) and sputum (41.34%) specimens, with a steady increase in sample types annually. A total of 7,211 strains were isolated, 76.43% of which were from respiratory tract specimens. The predominant pathogens included (31.17%), (30.11%), (14.05%), and (11.34%). The detection rates for (CRAB) were 61.88%, (CRKP) 29.28%, (CRPA) 5.80%, and (CREC) 3.04%. Susceptibility testing revealed fluctuating resistance rates for over the past 6 years. Notably, exhibited significant resistance to carbapenems (e.g., imipenem) and third-generation cephalosporins (e.g., ceftazidime).
From 2019 to 2024, the ICU experienced a severe problem with Gram-negative drug-resistant bacteria, particularly resistant to third-generation cephalosporins. isolates demonstrated resistance to most antibiotics, underscoring the need for continuous monitoring and the selection of effective antibiotics based on clinical practice.
本研究旨在调查四川省一家三级综合医院重症监护病房（ICU）革兰阴性菌的分布及耐药情况，以促进抗生素的合理使用并降低多重耐药性。
对2019年1月至2024年12月在ICU采集的样本中革兰阴性菌的分布及耐药情况进行回顾性分析。
共分析了83944份培养样本，主要是血液样本（45.27%）和痰液样本（41.34%），样本类型每年稳步增加。共分离出7211株菌株，其中76.43%来自呼吸道样本。主要病原体包括[具体细菌名称1]（31.17%）、[具体细菌名称2]（30.11%）、[具体细菌名称3]（14.05%）和[具体细菌名称4]（11.34%）。耐碳青霉烯类鲍曼不动杆菌（CRAB）的检出率为61.88%，耐碳青霉烯类肺炎克雷伯菌（CRKP）为29.28%，耐碳青霉烯类铜绿假单胞菌（CRPA）为5.80%，耐碳青霉烯类大肠埃希菌（CREC）为3.04%。药敏试验显示过去6年[具体细菌名称]的耐药率波动。值得注意的是，[具体细菌名称]对碳青霉烯类抗生素（如亚胺培南）和第三代头孢菌素（如头孢他啶）表现出显著耐药性。
2019年至2024年，ICU面临革兰阴性耐药菌的严重问题，尤其是对第三代头孢菌素耐药的[具体细菌名称]。[具体细菌名称]分离株对大多数抗生素耐药，强调需要持续监测并根据临床实践选择有效的抗生素。
